US2019191691A1PendingUtilityA1

Method for Enhancing Red Blood Cell Quality and Survival During Storage

73
Assignee: NEW HEALTH SCIENCES INCPriority: Aug 25, 2010Filed: Feb 28, 2019Published: Jun 27, 2019
Est. expiryAug 25, 2030(~4.1 yrs left)· nominal 20-yr term from priority
Inventors:Larry J. DumontTatsuro Yoshida
A01N 1/0242A01N 1/021A61M 1/0272C12N 5/0641A01N 1/142A01N 1/122
73
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is a method for enhancing the quality and survival of red blood cells during storage by depleting the red blood cells of both carbon dioxide and oxygen and maintaining 2,3-diphosphoglycerate acid levels.

Claims

exact text as granted — not AI-modified
1 .- 18 . (canceled) 
     
     
         19 . A stored oxygen and carbon dioxide depleted red blood cell composition comprising:
 oxygen and carbon dioxide depleted packed red blood cells;   reduced leukocytes;   reduced platelets;   reduced pathogens; and   an acidified additive solution.   
     
     
         20 . The composition of  claim 19 , wherein said oxygen and carbon dioxide depleted packed red blood cells comprise an oxygen level of 10 mmHg or less. 
     
     
         21 . The composition of  claim 19 , wherein said oxygen and carbon dioxide depleted packed red blood cells comprise a carbon dioxide level of 5 mmHg or less. 
     
     
         22 . The composition of  claim 19 , wherein said composition exhibits less than 0.2% hemolysis after three weeks of storage at 1 to 6° C. 
     
     
         23 . The composition of  claim 19 , wherein said composition exhibits less than 0.3% hemolysis after three weeks of storage at 1 to 6° C. 
     
     
         24 . The composition of  claim 19 , wherein said composition exhibits increased 2,3-DPG level for up to 42 days of storage compared to non-depleted red blood cells under the same storage conditions. 
     
     
         25 . The composition of  claim 19 , wherein said composition exhibits increased 2,3-DPG level for at least three weeks of storage compared to non-depleted red blood cells under the same storage conditions. 
     
     
         26 . The cell composition of  claim 19 , wherein said composition maintains 2,3-DPG level for at least two weeks. 
     
     
         27 . The red blood cell composition of  claim 19 , wherein said composition maintains 2,3-DPG level for at least three weeks compared to control. 
     
     
         28 . The composition of  claim 19 , wherein said composition maintains ATP levels at a higher level compared to control. 
     
     
         29 . The composition of  claim 19 , wherein said acidified additive solution has a pH ranging from 5.5 to 7.0. 
     
     
         30 . The composition of  claim 19 , wherein said acidified additive solution has a pH between 6.25 and 6.75. 
     
     
         31 . The composition of  claim 19 , wherein said stored oxygen and carbon dioxide depleted red blood cell composition is stored for at least three weeks. 
     
     
         32 . The composition of  claim 19 , wherein said stored oxygen and carbon dioxide depleted red blood cell composition is stored for at least seven weeks. 
     
     
         33 . The composition of  claim 19 , wherein said red blood cell composition further comprises saline. 
     
     
         34 . The composition of  claim 19 , wherein said red blood cell composition further comprises nutrients. 
     
     
         35 . The composition of  claim 19 , wherein said red blood cell composition further comprises an anticoagulant solution.

Join the waitlist — get patent alerts

Track US2019191691A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.